CompletedPhase 2

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

United States45 participantsStarted 2020-09-01

Plain-language summary

This study will evaluate the effects of a nutritional supplement called nicotinamide riboside in preventing small fiber nerve degeneration that is experimentally induced by applying capsaicin to skin in otherwise healthy study participants. Furthermore, the effects on nerve regeneration will also be evaluated. The results will be compared to a placebo control drug.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age: 18-65 * BMI\<32 * Normal neurological examination defined as Neuropathy Impairment Score \<2 Exclusion Criteria: * History of peripheral neuropathy * Any peripheral neuropathy risk factor including diabetes, Vitamin B12 deficiency, HIV-infection, chronic kidney or hepatic disease, hypothyroidism, chemotherapy or other know neurotoxic exposure.

What they're measuring

Denervation of Skin

Timeframe: 2 days

Reinnervation of Skin

Timeframe: 3 months

Trial details

NCT IDNCT03912220

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-01

Results submitted2024-04-15

View on ClinicalTrials.gov More Small Fiber Neuropathy trials